Tesamorelin 20 mg
Educational recon guide for a 20 mg Tesamorelin research vial and daily unit mapping. Research use only — not Egrifta pens.
Vial size
Same research phases — calculator defaults and unit math match the selected vial strength.
Vial
20 mg
Your BAC water
2 mL
Concentration
10.00 mg/mL
Per unit
~100.0 mcg
Frequency
Once daily subcutaneous (approved product is daily)
Route
Subcutaneous (abdomen on approved product)
Live reconstitution calculator
Defaults match this guide (20 mg + 2 mL BAC). Change water or dose and the unit tables below update automatically.
Step 1
Reconstitution
Peptide amount in the vial and how much bacteriostatic water you add.
Step 2
Your dose
Quick-select common research doses (includes 2.5 / 7.5 for dual-agonist ladders) or type any mg / mcg value.
Quick select (mg) — switch units or type any value
Suggested: 30-unit barrel (smallest that fits this draw).
Your draw
Results
Total draw
10 units
Volume
0.100 mL
Doses per vial
20
Syringes needed
1
Barrel
30-unit
Fits one syringe?
Yes
30-unit · 0.3 mL
Filled to 10 u
Fill one 30-unit U-100 syringe to about 10 units (0.100 mL).
Research cycle phases
Units and volumes recompute from your Step 1 concentration (2 mL BAC → 10.00 mg/mL · 100.0 mcg/unit). Doses below are once daily during the course — not weekly.
Standard course
Approved tesamorelin (Egrifta) uses about ~1.4 mg SC daily for the classic vial presentation; Egrifta WR uses about ~1.28 mg daily. Research-market powder is not the pharmaceutical product.
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Daily · 1.0 mg (tolerability step) | 1 mg1,000 mcg | 10 u | 0.10 mLLower educational amount |
| Daily · 1.4 mg (approved-style classic) | 1.40 mg1,400 mcg | 14 u | 0.14 mLMatches classic Egrifta ~1.4 mg daily educational target |
Alternate / higher courses
Shorter or higher daily courses discussed in research communities — not a clinical recommendation
| Phase | Daily dose | Units | Volume |
|---|---|---|---|
| Daily · 2.0 mg | 2 mg2,000 mcg | 20 u | 0.20 mLAbove approved daily amount — educational only |
Supplies planner
Using the guide’s phase ladder (1 mg → 1.4 mg per injection (phase ladder)) over a 42-day course. Set a dose in Step 2 to plan supplies at your own amount.
Your recon
2 mL · 10.00 mg/mL
Dose in plan
Phase ladder
Syringe size
100-unit
Horizon
42-day course
Tesamorelin 20 mg vials
3 vials
~53.2 mg mg total peptide over this 42-day course at 1 mg → 1.4 mg per injection (phase ladder). Each vial holds 20 mg.
Bacteriostatic water
2 × 3 mL or 1 × 10 mL
2 mL BAC per vial × 3 vials = 6.0 mL total. Buy as 2× 3 mL bottles or 1× 10 mL bottle (whichever you stock).
U-100 insulin syringes (100-unit)
42+ syringes
About one 100-unit syringe per injection for this schedule. Keep a few spares.
Alcohol swabs & sharps
~90 swabs · 1 sharps container
Wipe vial stopper and injection site each time. Dispose needles in a proper sharps container.
Reconstitution steps
- Allow the lyophilized 20 mg Tesamorelin vial and bacteriostatic water to reach room temperature.
- Draw 2.0 mL bacteriostatic water (default for this guide).
- Inject BAC slowly down the inner wall of the vial — avoid blasting the powder cake.
- Gently swirl or roll until the solution is clear. Do not shake hard (foaming).
- Label with recon date and concentration (e.g. "10.0 mg/mL").
- Refrigerate at 2–8 °C (35–46 °F), protected from light. Prefer using a reconstituted multi-dose vial within ~28 days with sterile technique.
Storage
Lyophilized
Keep dry powder cold and dark when possible (−20 °C / −4 °F preferred for long-term research stock).
Reconstituted
Refrigerate at 2–8 °C (35–46 °F). Avoid freeze–thaw of the working solution. Prefer finishing within ~28 days.
- ·Write recon date and BAC volume on the label.
- ·Protect from light during storage.
- ·Discard if cloudy, particulates, or odd odor appear after reconstitution.
Protocol notes
- ·GHRH analog approved for reduction of excess abdominal fat in HIV-associated lipodystrophy as Egrifta.
- ·Research powders ≠ Egrifta.
- ·Research use only.
Research context & considerations
Tesamorelin is an FDA-approved GHRH analog for a specific HIV lipodystrophy indication. Research-market vials are not that product.
- ·GH-axis effects: edema, arthralgia, glucose changes possible.
- ·Active malignancy is a major caution context for GH-axis agents.
- ·Not for casual body-recomp use as medical advice.
- ·Pregnancy out of scope.
Catalog match
Tesamorelin (TSM20)
20mg x 10 vials · from $120